{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:49:20Z","timestamp":1791510560667,"version":"4.3.4"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Given the high costs of treatment with proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9i) and the limited US Food and Drug Administration label for these treatments in patients with stroke due to atherosclerotic disease, it is unknown whether these agents are cost-effective for reducing recurrent stroke events.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the theoretical cost-effectiveness of currently available PCSK9i for the prevention of recurrent stroke in patients with high-risk intracranial arterial stenosis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation was a post hoc trial-based cost-effectiveness analysis of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial from a health care sector perspective. Adult patients with stroke due to intracranial arterial stenosis were included in SAMMPRIS and randomized to aggressive medical management with or without intracranial arterial stenting. Patients from the SAMMPRIS trial with complete covariate data were included in this secondary analysis. Data were analyzed from January to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n A base-case assumption of 32% relative risk reduction for stroke among PCSK9i based on its low-density lipoprotein\u2013lowering effect.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Based on trial-estimated transition probabilities, annual direct-to-consumer prices for 3 PCSK9i (alirocumab: $6600; evolocumab: $7200; and inclisiran: $7920) and estimated US-based stroke care costs in 2025 US dollars, a decision-analytic Markov cohort model was developed to estimate the cost-effectiveness of PCSK9i for reducing recurrent stroke over a 5-year time horizon, with a 7% annual drug discontinuation rate and a 3% discount rate for future costs and quality-adjusted life-year (QALYs). From 1000 Monte Carlo simulations, the probability of cost-effectiveness of 3 PCSK9i was estimated at a $120\u202f000\/QALY threshold. Sensitivity analyses evaluated at an alternative threshold ($50\u202f000\/QALY), treatment efficacy (20% to 50%), and stroke care costs (50% to 150% of base estimates). A patient perspective analysis reflecting patients\u2019 out-of-pocket costs with insurance coverage was also conducted.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 367 patients from the SAMMPRIS included in this study, 88 were Black (24.0%), 260 were White (70.8%), and 19 Asian, Native Hawaiian or Pacific Islander, more than 1 race, or other (5.2%), and the median (IQR) age at enrollment was 59 (52-69) years. At current direct-to-consumer prices, the probability of cost-effectiveness at a willingness-to-pay threshold of $120\u202f000\/QALY over a 5-year horizon was 58.6% (95% CI, 55.5%-61.6%) for alirocumab, 53.8% (95% CI, 50.7%-56.9%) for evolocumab, and 36.7% (95% CI, 33.8%-39.7%) for inclisiran.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This theoretical framework suggests that alirocumab and evolocumab were cost-effective for preventing recurrent stroke in patients with severe intracranial atherosclerosis, with all agents cost-effective under current cost-sharing programs offered by commercial and Medicare plans.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.10707","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:00:16Z","timestamp":1777993216000},"page":"e2610707","source":"Crossref","is-referenced-by-count":1,"title":["Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis"],"prefix":"10.1001","volume":"9","author":[{"given":"Caroline","family":"Kellogg","sequence":"first","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Badillo Goicoechea","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Yaghi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lifespan Hospital, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemant","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mehendale","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Orjuela","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Kass-Hout","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami Z.","family":"Morsi","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eesha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Prabhakaran","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Brorson","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Golani","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Mazuera","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Kang","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Eltatawy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pillajo","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Siegler","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"11","key":"zoi260325r1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease.","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin Ther"},{"issue":"7","key":"zoi260325r2","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"5","key":"zoi260325r3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis.","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"issue":"1","key":"zoi260325r4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213768","article-title":"Estimated theoretical benefit of aggressive ldl lowering in patients with symptomatic intracranial atherosclerosis.","volume":"105","author":"Siegler","year":"2025","journal-title":"Neurology"},{"issue":"1","key":"zoi260325r5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"18","key":"zoi260325r6","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1161\/CIR.0000000000001377","article-title":"2025 AHA\/ACC statement on cost\/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"152","author":"Kazi","year":"2025","journal-title":"Circulation"},{"issue":"15","key":"zoi260325r7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine.","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"issue":"17","key":"zoi260325r8","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia.","volume":"74","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"zoi260325r9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study.","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"18","key":"zoi260325r10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi260325r11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control.","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"issue":"9914","key":"zoi260325r12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(13)62038-3","article-title":"Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.","volume":"383","author":"Derdeyn","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"zoi260325r13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(20)30079-X","article-title":"Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study.","volume":"19","author":"Hurford","year":"2020","journal-title":"Lancet Neurol"},{"issue":"12","key":"zoi260325r14","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1161\/STROKEAHA.109.561365","article-title":"Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale.","volume":"40","author":"Hong","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"zoi260325r15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/B:QURE.0000018496.02968.50","article-title":"Assessment of poststroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQoL-5D.","volume":"13","author":"van Exel","year":"2004","journal-title":"Qual Life Res"},{"issue":"3","key":"zoi260325r16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00019053-200321030-00004","article-title":"A meta-analysis of quality-of-life estimates for stroke.","volume":"21","author":"Tengs","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"zoi260325r17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial.","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"25","key":"zoi260325r18","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of alirocumab on stroke in ODYSSEY Outcomes.","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"zoi260325r19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1105335","article-title":"Stenting versus aggressive medical therapy for intracranial arterial stenosis.","volume":"365","author":"Chimowitz","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260325r20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes.","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"zoi260325r21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials.","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"zoi260325r22","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the Glagov randomized clinical trial.","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"44","key":"zoi260325r23","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY Outcomes trial.","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"zoi260325r24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005858","article-title":"Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY Outcomes trial.","volume":"12","author":"Szarek","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848614\/kellogg_2026_oi_260325_1777322753.4587.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:00:16Z","timestamp":1777993216000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.10707","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}